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ORIGINAL ARTICLEBurden of extensively drug-resistant and pandrug-resistant Gram-negative
bacteria at a tertiary-care centrePuneet Bhatt, Kundan Tandel, Vishal Shete and K. R. Rathi
Command Hospital, Pune, IndiaAbstractThe emergence of resistance to multiple antimicrobial agents in Gram-negative bacteria is a signiﬁcant threat to public health, as it restricts
the armamentarium of the clinician against these infections. The aim of this study was to determine the burden of extensively drug-resistant
(XDR) and pandrug-resistant (PDR) Gram-negative bacteria at a tertiary-care centre. Antimicrobial susceptibility testing of 1240 clinical
isolates of Gram-negative bacteria obtained from various clinical samples during the study period was carried out by the Kirby-Bauer disc
diffusion method. Minimum inhibitory concentration of all antibiotics including tigecycline and colistin was determined by Vitek-2
automated susceptibility testing system. Out of 1240 isolates of Gram-negative bacteria, 112 isolates (9%) were resistant to all the
antibiotics tested by Kirby-Bauer disc diffusion method. This ﬁnding was corroborated by Vitek-2. In addition, Vitek-2 found that 67
isolates were resistant to all antibiotics except tigecycline and colistin. A total of 30 isolates were susceptible to only colistin, and four
isolates were susceptible to only tigecycline. It was also found that six isolates (excluding ﬁve isolates of Proteus spp.) were resistant to
both colistin and tigecycline. Thus, 101 (8.1%) out of 1240 isolates were XDR and 11 isolates (0.9%) were PDR. The ﬁndings of this
study reveal increased burden of XDR and PDR Gram-negative bacteria in our centre. It also highlights the widespread dissemination of
these bacteria in the community. This situation warrants the regular surveillance of antimicrobial resistance of Gram-negative bacteria
and implementation of an efﬁcient infection control program.
© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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E-mail: puneetbhatt@gmail.comIntroductionOf late, the medical community worldwide has been witness to
an increase in infections due to Gram-negative bacteria, which
are resistant to many classes of antibiotics [1]. These infections
are an important cause for prolonged hospitalization, leading to
increased treatment costs and poor patient outcome in the
form of increased morbidity and mortality [2]. These resistant
pathogens were earlier considered to be primarily nosocomial
pathogens, but it is now evident that they have spread to the
community [3]. The emergence of resistance to multiplew Microbe and New Infect 2015; 8: 166–170
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niﬁcant threat to public health, as there are fewer, or some-
times even no, effective antimicrobial agents available for
infections caused by these bacteria [4].
In the medical jargon to date, there is no consensus on the
deﬁnitions and use of terms such as ‘multidrug resistant’
(MDR), ‘extensively drug resistant’ (XDR) and ‘pandrug resis-
tant’ (PDR), which depict resistance in multidrug-resistant or-
ganisms [4]. A proposition for deﬁning these resistant bacteria
was discussed in a joint program by European Centre for
Disease Prevention and Control (ECDC) and the US Centers
for Disease Control and Prevention (CDC). They formulated
few deﬁnitions and deﬁned XDR bacteria as ‘isolates being non-
susceptible to at least one agent in all but 2 or fewer antimi-
crobial categories listed in the Clinical and Laboratory Stan-
dards Institute (CLSI) guidelines’ and PDR bacteria as ‘isolatesiety of Clinical Microbiology and Infectious Diseases.
nses/by-nc-nd/4.0/)
TABLE 1. Species distribution of extensively resistant and
pandrug-resistant Gram-negative bacteria by disc diffusion
method (n [ 112)
Sample Organism
Total
isolates
Resistant
isolates %
NMNI Bhatt et al. Burden of pandrug-resistant bacteria 167being non-susceptible to all agents in all antimicrobial categories
for each bacterium’ [4].
This study was carried out with an aim to determine the
burden of XDR and PDR Gram-negative bacteria at a tertiary-
care centre in Pune, India.1. Escherichia coli 625 18 2.9
2. Klebsiella pneumoniae 269 32 11.9
3. Pseudomonas aeruginosa 172 34 19.8
4. Acinetobacter baumannii 123 19 15.4Materials and methods
5. Proteus spp. 40 5 12.5
6. Enterobacter spp. 6 2 33.3
7. Raoultella ornithinolytica 1 1 100
8. Hafnia alvei 1 1 100
9. Salmonella typhi 1 — —
10. Stenotrophomonas maltophilia 1 — —
11. Serratia marcescens 1 — —This study was carried out from July to September 2014 at a
large tertiary-care centre. A total of 1240 nonrepetitive clinical
isolates of Gram-negative bacteria were identiﬁed from various
clinical specimens received in the microbiology laboratory with
the help of conventional phenotypic methods.
Antimicrobial susceptibility testing was carried out by Kirby-
Bauer disc diffusion method, and the results were interpreted
according to CLSI guidelines [5].
Minimum inhibitory concentration (MIC) for all the isolates
which were resistant to all the antibiotics by disc diffusion
method was determined by Vitek-2 automated susceptibility
testing method.ResultsA total of 1240 nonrepetitive clinical isolates of Gram-negative
bacteria were identiﬁed by conventional phenotypic methods
from various clinical samples received in the microbiology
laboratory of a tertiary-care centre.
The most commonly isolated Gram-negative bacteria was
Escherichia coli (625/1240), followed by Klebsiella pneumoniae
(269/1240), Pseudomonas aeruginosa (172/1240), Acinetobacter
baumannii (123/1240), Proteus spp. (40/1240), Enterobacter spp.
(6/1240) and others (5/1240).
Out of these 1240 isolates of Gram-negative bacteria,
112 isolates (9%) were resistant to all the antibiotics tested
by Kirby-Bauer disc diffusion method. The distribution of these
resistant isolates is listed in Table 1. The most common isolate
found to be resistant to all antibiotics tested was P. aeruginosa,
followed by K. pneumoniae, A. baumannii, E. coli and Proteus spp.
The most common sample from which these 112 isolates
were obtained was urine (37.5%), followed by wound swab/pus
(22.3%), tracheal aspirates (17.9%), blood (7.1%), cerebrospinal
ﬂuid (7.1%), central line tip (4.5%) and other miscellaneous
samples (3.6%). The sample-wise distribution of these resistant
isolates is shown in Fig. 1.
The ward-wise distribution of isolates is shown in Fig. 2. Most
of the resistant isolates were obtained from acute wards (42.9%)
and intensive care units (ICUs) (29.5%), followed by other wards
(23.2%) and the outpatient department (OPD) (4.4%).© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf
This is an open access artiMIC of all antibiotics was determined by Vitek-2 automated
susceptibility testing system using GN-AST cards. It was found
that 67 isolates were resistant to all antibiotics except tigecy-
cline and colistin. A total of 30 isolates were susceptible to only
colistin, of which 29 were P. aeruginosa and one was
A. baumannii. Four isolates were susceptible to only tigecycline,
out of which two were K. pneumoniae and two were
A. baumannii. A total of six isolates were resistant to both
colistin and tigecycline, out of which three were P. aeruginosa,
two were K. pneumoniae and one was Hafnia alvei. As Proteus
spp. are intrinsically resistant to tigecycline and colistin, testing
for these antibiotics against Proteus spp. was not done by Vitek-
2. Thus, 101 (8.1%) of 1240 isolates were XDR, and 11 isolates
(0.9%) were PDR. The species distribution of XDR and PDR
Gram-negative bacteria is shown in Table 2.
The most common sample from which PDR isolates were
obtained was urine (6/11), followed by tracheal aspirate (3/11)
and pus (2/11). These PDR isolates were mainly obtained from
ICUs (6/11) and acute wards (5/11). No PDR isolate was ob-
tained from other wards or OPD.DiscussionAntimicrobial resistance is a worldwide problem that knows no
international boundaries and can spread between continents
[6]. Emergence of resistance to multiple antimicrobial agents in
pathogenic bacteria has become a signiﬁcant threat to public
health, as there are fewer, or sometimes even no, effective
antimicrobial agents available for infections caused by these
bacteria [4]. Of late, terms such as ‘multidrug resistance’ have
been used in medical literature to describe isolates of Myco-
bacterium tuberculosis resistant to rifampicin and isoniazid. A
group of international experts came together in a joint initiative
of the ECDC and CDC to deliberate and describe different
patterns of resistance found in healthcare-associated,of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 166–170
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 2. Ward-wise distribution of resistant
isolates.
FIG. 1. Sample-wise distribution of resistant
isolates.
168 New Microbes and New Infections, Volume 8 Number C, November 2015 NMNIantimicrobial-resistant bacteria. According to ECDC and CDC,
MDR is deﬁned as nonsusceptibility to at least one agent in
three or more antimicrobial categories, XDR is deﬁned as the
nonsusceptibility to at least one agent in all but two or fewer
antimicrobial categories while PDR is deﬁned as non-
susceptibility to all agents in all antimicrobial categories for each
bacterium [4,7].
During the last few years, there has been a signiﬁcant
increase in infections caused by Gram-negative bacteria, which
are resistant to several classes of antibiotics [1]. These
infections are an important cause for prolonged hospitalization,
increasing the treatment costs and also leading to poorTABLE 2. Species distribution of extensively resistant and pandrug
Resistance or susceptibility Escherichia coli
Kleb
pne
Resistant to all antibiotics except tigecycline and colistin 18 28
Susceptible only to tigecycline — 2
Susceptible only to colistin — —
Resistant to all antibiotics including tigecycline and colistin — 2
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mortality [2].
During the few decades, all the efforts to combat MDR
microorganisms were largely focused on Gram-positive bacte-
ria. Unfortunately, the problems of MDR Gram-negative bac-
teria were not accompanied by advances in pertinent
therapeutic options [6,8]. Thus, to prevent the world from
reverting to the travails of preantibiotic era, it is now an
opportune time to intensify attention towards Gram-negative
resistance.
This study was carried out to determine the burden of XDR
and PDR Gram-negative bacteria at a tertiary-care centre.-resistant Gram-negative bacteria
siella
umoniae
Pseudomonas
aeruginosa Proteus spp.
Acinetobacter
baumannii Other
2 — 16 3
— — 2 —
29 — 1 —
3 5 — 1
iety of Clinical Microbiology and Infectious Diseases, NMNI, 8, 166–170
nses/by-nc-nd/4.0/)
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period, 112 isolates (9%) were found to be resistant to all the
antibiotics tested by Kirby-Bauer disc diffusion method. The
most common isolate which was found to be resistant to all
antibiotics tested was P. aeruginosa, followed by K. pneumoniae,
A. baumannii, E. coli and Proteus spp. (Table 1).
It is clear from Fig. 1 that the most common sample from
which these resistant isolates were obtained was urine (37.5%),
followed by wound swab/pus (22.3%), tracheal aspirates
(17.9%) and others. Most of the isolates were obtained from
acute wards (42.9%) and ICUs (29.5%) followed by other wards
(23.2%). It was interesting to note that ﬁve isolates (4.4%) were
also obtained from patients attending OPD. The ﬁnding that
these XDR isolates have been isolated from the OPD patients
corroborates with other studies [3].
As there is no disc diffusion interpretive criteria in CLSI
guidelines for drugs such as colistin and tigecycline, all 112
isolates were subjected to automated susceptibility testing by
Vitek-2 (bioMérieux) using GN-AST cards, and MICs of various
antibiotics was determined. The results of Vitek-2 were in
concordance with Kirby-Bauer disc diffusion testing, as all the
112 isolates were found to be resistant to all the antibiotics
tested by both methods.
The growing resistance among Gram-negative bacteria to
commonly used antibiotics has led to the resurgence of the use
of previously discarded antibiotics such as colistin as a last-
resort treatment option. However, the use of colistin has its
own disadvantages because it is a neurotoxic and nephrotoxic
agent [9]. Despite the toxicity of this relatively old agent, colistin
is frequently used to treat infections due to carbapenem-
resistant Enterobacteriaceae. In most cases, colistin is the last
viable effective option for the treatment of invasive bloodstream
infections that are due to carbapenemase-producing Gram-
negative bacteria. Overuse of colistin has recently led to the
emergence of resistance to this lifesaving agent [9,10].
Tigecycline is a minocycline derivative belonging to the new
class of antimicrobial drugs known as glycylcyclines. It was the
ﬁrst glycylcycline antibiotic to be approved by the US Food and
Drug Administration in June 2005 [11]. It is a broad-spectrum
antimicrobial drug with activity against many Gram-positive,
Gram-negative and anaerobic pathogens and has been regu-
larly prescribed as a part of combination schemes against
carbapenem-resistant Enterobacteriaceae and also
Carbapenem-resistant A. baumannii [12,13]. Unfortunately,
tigecycline is not active against P. aeruginosa [11]. Despite some
differences in the reported susceptibility breakpoints of this
drug (1 or 2 mg/L), it has been shown in many surveillance
studies that tigecycline presents good in vitro activity against
many MDR and XDR Enterobacteriaceae and A. baumannii
isolates [14].© 2015 New Microbes and New Infections published by Elsevier Ltd on behalf
This is an open access artiApart from the antibiotics tested by disc diffusion method,
Vitek-2 also determined the MICs of tigecycline and colistin. Of
these 112 isolates, 67 isolates were found to be susceptible to
both tigecycline and colistin but were resistant to other
antibiotics.
A total of 30 isolates were found to be susceptible to only
colistin, out of which 29 were P. aeruginosa and one was
A. baumannii. As mentioned earlier, in case of MDR Gram-
negative organisms, the need for alternative treatments has
lead to the resurgence of colistin use. Although colistin has
been shown to be effective for the treatment of a wide variety
of infections, its use for treating infections caused by these
three Gram-negative organisms has been impeded by occur-
rences of colistin resistance. Development of resistance to
colistin is a serious concern [15]. In the present study, four
isolates of K. pneumoniae, three isolates of P. aeruginosa and two
isolates of A. baumannii were resistant to colistin, in addition to
other antibiotics tested by disc diffusion, which is a cause for
concern. As colistin is the last line of defense against these
virulent pathogens, resistance to this antibiotic may have
devastating effects if no other treatment options are available to
combat the infection.
In the present study, two isolates of K. pneumoniae and one
isolate of A. baumannii were resistant to tigecycline, which is an
important ﬁnding. As P. aeruginosa is intrinsically resistant to
tigecycline, its susceptibility testing was not evaluated by Vitek-
2. Tigecycline resistance among Gram-negative bacteria such as
K. pneumoniae and A. baumannii is rare but has been reported in
a few studies [16,17]. Four isolates were susceptible to only
tigecycline, of which two were K. pneumoniae and two were
A. baumannii.
The most important ﬁnding of our study was that a total of six
isolates were resistant to both colistin and tigecycline, out of
which three were P. aeruginosa, two were K. pneumoniae and one
was H. alvei. Proteus spp. are intrinsically resistant to tigecycline
and colistin, so testing for these antibiotics against Proteus spp.
was not done by Vitek-2. Thus, 101 (8.1%) of 1240 isolates were
nonsusceptible to two or fewer class of antimicrobials and were
XDR, which is less than that reported by Bajpai et al. [6], who
reported 12%XDR. A total of 11 isolates (0.9%)were PDR, being
resistant to all antimicrobials including colistin and tigecycline.
This prevalence of 0.9% PDR Gram-negative bacteria in the
present study is also less than that reported by Bajpai et al. [6],
who reported 2.1% of bacteria to be PDR.ConclusionThe prevalence of extensive drug resistance and PDR among
Gram-negative bacterial isolates was 8.1% and 0.9%,of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 166–170
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
170 New Microbes and New Infections, Volume 8 Number C, November 2015 NMNIrespectively, which is disturbingly high. These ﬁndings are
alarming because infections with these XDR and PDR Gram-
negative bacteria leave clinicians with no treatment options,
leading to increased morbidity and mortality. The other
important ﬁnding of this study is that few XDR isolates were
obtained from patients attending OPD. This is a cause for
concern, as it can be deduced that these resistant bacteria have
disseminated in the community. The growing resistance of
Gram-negative organisms and the emergence of XDR and PDR
strains need to be curbed. This situation warrants the imple-
mentation of an efﬁcient infection control program and inten-
sive surveillance of antimicrobial resistance of Gram-negative
bacteria so as to establish a rational antibiotic stewardship
program for the sustainable management of such infections.Conﬂict of interestNone declared.References[1] Sharma R, Sharma CL, Kapoor B. Antibacterial resistance: current
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